NASDAQ: RCELAvita Medical Inc Stock
$5.88+0.18 (+3.16%)
Updated Jul 14, 2025
RCEL Price
$5.88
Fair Value Price
N/A
Market Cap
$155.44M
52 Week Low
$4.71
52 Week High
$14.16
P/E
-2.68x
P/B
-34x
P/S
2.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$71.66M
Earnings
-$57.05M
Gross Margin
85.5%
Operating Margin
-72.25%
Profit Margin
-79.6%
Debt to Equity
-16.2
Operating Cash Flow
-$38M
Beta
1.39
Next Earnings
Aug 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RCEL Overview
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RCEL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
RCEL
Ranked#73 of 105
Ranked#73 of 105
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.86 | A | |
| $225.79 | A | |
| $30.04 | A |
Be the first to know about important RCEL news, forecast changes, insider trades & much more!
RCEL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RCEL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RCEL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RCEL due diligence checks available for Premium users.
Valuation
RCEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.68x
Industry
36.01x
Market
31.22x
RCEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-34x
Industry
4.07x
RCEL's financial health
Profit margin
Revenue
$18.5M
Net Income
-$13.9M
Profit Margin
-74.9%
RCEL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$69.6M
Liabilities
$74.1M
Debt to equity
-16.2
RCEL's short-term assets ($47.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RCEL's long-term liabilities ($51.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RCEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.3M
Investing
$10.8M
Financing
$363.0k
RCEL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RCEL vs Medical Device Stocks
Avita Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.